This company listing is no longer active
AMNI Stock Overview
Develops stem cell-based therapeutics to treat severe life-threatening diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Amniotics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0054 |
| 52 Week High | SEK 0.051 |
| 52 Week Low | SEK 0.0012 |
| Beta | 0.53 |
| 1 Month Change | 8.00% |
| 3 Month Change | -3.57% |
| 1 Year Change | -88.93% |
| 3 Year Change | -99.96% |
| 5 Year Change | n/a |
| Change since IPO | -99.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| AMNI | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 8.0% | 1.7% | 3.3% |
| 1Y | -88.9% | -2.7% | -2.4% |
Return vs Industry: AMNI underperformed the Swedish Biotechs industry which returned 30.2% over the past year.
Return vs Market: AMNI underperformed the Swedish Market which returned 24.5% over the past year.
Price Volatility
| AMNI volatility | |
|---|---|
| AMNI Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in SE Market | 13.5% |
| 10% least volatile stocks in SE Market | 4.2% |
Stable Share Price: AMNI has not had significant price volatility in the past 3 months.
Volatility Over Time: AMNI's weekly volatility has decreased from 25% to 10% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 4 | Marcus Larsson | www.amniotics.com |
Amniotics AB (publ) develops stem cell-based therapeutics to treat severe life-threatening diseases. The company’s lead drug candidate is PulmoStem for the treatment of lung disease. It also develops CogniStem for the treatment of CNS indications; NephroStem for the treatment of kidney-specific indications; CutiStem for the treatment of dermatological indications; and AMNI-NK003.
Amniotics AB (publ) Fundamentals Summary
| AMNI fundamental statistics | |
|---|---|
| Market cap | SEK 14.76m |
| Earnings (TTM) | -SEK 20.19m |
| Revenue (TTM) | SEK 2.45m |
6.0x
P/S Ratio-0.7x
P/E RatioIs AMNI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMNI income statement (TTM) | |
|---|---|
| Revenue | SEK 2.45m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 2.45m |
| Other Expenses | SEK 22.64m |
| Earnings | -SEK 20.19m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 18, 2025
| Earnings per share (EPS) | -0.0074 |
| Gross Margin | 100.00% |
| Net Profit Margin | -824.04% |
| Debt/Equity Ratio | 0% |
How did AMNI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/30 11:35 |
| End of Day Share Price | 2024/09/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amniotics AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Carl Ramanius | Redeye |